Mode
Text Size
Log in / Sign up

Adequate treatment for maternal syphilis reduces stillbirth odds by 84% in pregnant womenAdequate Treatment for Syphilis Linked to Lower Stillbirth Rates

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that adequate treatment for maternal syphilis reduces stillbirth odds by 84% compared to inadequate coverage.

This meta-analysis evaluates the impact of treatment adequacy on stillbirth prevalence among pregnant women with confirmed maternal syphilis. The study synthesizes global data to compare outcomes between regions and treatment statuses. The pooled stillbirth prevalence was 5.02% (95% CI 2.44-10.06%).

Key findings indicate significant geographic variation, with Sub-Saharan Africa showing a 10.93% stillbirth prevalence compared to 1.57% in Asia (P <.001). More importantly, treatment adequacy was linked to lower risk; stillbirth prevalence was 11.69% in cases of low or absent coverage versus 2.81% in cases of moderate-to-high coverage (Q = 22.1, P <.001). Furthermore, adequate treatment was associated with 84% lower adjusted odds of stillbirth (adjusted odds ratio = 0.16).

The authors note high heterogeneity (I2 = 90.67%) in the pooled prevalence. They also caution that regional estimates may be confounded by differences in treatment coverage. Clinically, the data suggest that early diagnosis and timely, stage-appropriate therapy are the most critical factors in reducing stillbirth risk, rather than geography alone.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the specific impact of treatment adequacy on outcomes for maternal syphilis. It builds upon prior evidence showing a 5.20-fold higher syphilis prevalence in low-income countries among forcibly displaced populations. While previous data highlighted high prevalence in specific regions, this study identifies treatment adequacy as the primary driver of reduced stillbirth risk, providing a clearer clinical pathway for intervention.

This review looked at the link between syphilis treatment and stillbirth rates among pregnant women. The study analyzed data from various regions to see how the quality of medical care affected outcomes for babies. The researchers found that the overall stillbirth rate was 5.02%.

Data showed a major difference based on treatment quality. In areas where treatment was low or absent, the stillbirth rate was 11.69%. In areas with moderate to high treatment coverage, the rate dropped to 2.81%. The study also noted that while geography played a role, the level of treatment was the most important factor for improving outcomes.

Because of high variation in the data, these results should be viewed as a link rather than a direct guarantee. The study suggests that early diagnosis and proper therapy are key. Patients should talk to their doctors about the importance of timely and complete treatment during pregnancy.

What this means for you:
Adequate syphilis treatment for pregnant women is linked to significantly lower odds of stillbirth.

Common questions

How does treatment adequacy affect stillbirth rates?

The study found that adequate treatment is linked to a significant reduction in stillbirth. Specifically, areas with moderate to high treatment coverage saw a stillbirth rate of 2.81%, while areas with low or absent coverage saw a much higher rate of 11.69%.

What was the overall stillbirth rate found in the study?

The study reported a pooled stillbirth prevalence of 5.02%. However, there was high variation in the data across different regions, which means the results can vary depending on the specific circumstances of the medical care provided.

Does geography play a role in these outcomes?

The study found different rates by region, with Sub-Saharan Africa showing a rate of 10.93% and Asia showing 1.57%. However, the researchers noted that the level of treatment adequacy was the most clinically important factor for reducing stillbirth risk.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
OBJECTIVES: Maternal syphilis remains a major cause of adverse pregnancy outcomes, with stillbirth among the most severe. We aimed to estimate the global prevalence of stillbirth among pregnancies complicated by syphilis and to evaluate associated determinants. METHODS: This systematic review and meta-analysis searched four databases for studies reporting stillbirth among pregnant women with confirmed maternal syphilis. Random-effects meta-analysis was performed on logit-transformed prevalence estimates. Heterogeneity was assessed using I² and τ² statistics. Subgroup analyses explored geographic region and treatment adequacy; treatment-stratified estimates were prioritized because treatment exposure differed substantially across studies. Risk of bias was also assessed. RESULTS: Eleven studies met the inclusion criteria. The pooled prevalence of stillbirth was 5.02% (95% confidence interval 2.44-10.06%) with substantial heterogeneity (I² = 90.67%). Stillbirth prevalence was highest in sub-Saharan Africa (10.93%) and lowest in Asia (1.57%; P < .001), although regional estimates were potentially confounded by differences in treatment coverage. Treatment-stratified prevalence was 11.69% in studies with low or absent treatment coverage and 2.81% in studies with moderate-to-high coverage (Q = 22.1, P < .001). In one included study, adequate treatment was associated with 84% lower adjusted odds of stillbirth (adjusted odds ratio = 0.16); this relative effect should not be interpreted as a 16% breakthrough rate. No significant publication bias was detected. CONCLUSIONS: Maternal syphilis remains a significant but preventable cause of stillbirth. Treatment adequacy, rather than geography alone, was the most clinically important source of variation. Early diagnosis and timely, stage-appropriate therapy substantially reduce stillbirth. Strengthening antenatal screening and ensuring prompt treatment are critical to achieving global elimination of congenital syphilis-related mortality.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.